MRK•benzinga•
Merck Announced That Health Canada Approved Keytruda (Pembrolizumab), Merck's Anti-PD-1 Therapy, In Combination With Carboplatin And Paclitaxel, Followed By Keytruda As A Single Agent, For The Treatment Of Adult Patients With Primary Advanced Or Recurrent
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 19, 2025 by benzinga